Caliway secures FDA clearance for CBL-514 clinical trial

​Caliway Biopharmaceuticals has received the US FDA clearance for its CBL-0302 IND application, enabling a pivotal Phase III clinical trial of CBL-514 for abdominal subcutaneous fat reduction.

The post Caliway secures FDA clearance for CBL-514 clinical trial appeared first on Hospital Management.

 

Back to the Featured Stories

Featured Stories

Jade reports interim Phase I results of JADE101 for IgAN
MicroPort launches LBBOT Solution commercially in Europe and Australia
Servier to acquire Edgewise’s muscular dystrophy business for $2.65bn
SKIA secures FDA 510(k) clearance for AR surgical platform
FDA approves AstraZeneca’s Imfinzi-BCG combination for NMIBC therapy

Connect with us

Whether you are a professional looking for a new job or a representative of an organization who needs workforce solutions - we are here to help.

Contact Us